TY - JOUR
T1 - Blood-based biomarkers for Alzheimer's disease
T2 - Current state and future use in a transformed global healthcare landscape
AU - Hampel, Harald
AU - Hu, Yan
AU - Cummings, Jeffrey
AU - Mattke, Soeren
AU - Iwatsubo, Takeshi
AU - Nakamura, Akinori
AU - Vellas, Bruno
AU - O'Bryant, Sid
AU - Shaw, Leslie M.
AU - Cho, Min
AU - Batrla, Richard
AU - Vergallo, Andrea
AU - Blennow, Kaj
AU - Dage, Jeffrey
AU - Schindler, Suzanne E.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/9/20
Y1 - 2023/9/20
N2 - Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker-guided targeted therapies that may be most effective when provided early in the disease. Currently, diagnosis and management of early AD are largely guided by clinical symptoms. FDA-approved neuroimaging and cerebrospinal fluid biomarkers can aid detection and diagnosis, but the clinical implementation of these testing modalities is limited because of availability, cost, and perceived invasiveness. Blood-based biomarkers (BBBMs) may enable earlier and faster diagnoses as well as aid in risk assessment, early detection, prognosis, and management. Herein, we review data on BBBMs that are closest to clinical implementation, particularly those based on measures of amyloid-β peptides and phosphorylated tau species. We discuss key parameters and considerations for the development and potential deployment of these BBBMs under different contexts of use and highlight challenges at the methodological, clinical, and regulatory levels.
AB - Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker-guided targeted therapies that may be most effective when provided early in the disease. Currently, diagnosis and management of early AD are largely guided by clinical symptoms. FDA-approved neuroimaging and cerebrospinal fluid biomarkers can aid detection and diagnosis, but the clinical implementation of these testing modalities is limited because of availability, cost, and perceived invasiveness. Blood-based biomarkers (BBBMs) may enable earlier and faster diagnoses as well as aid in risk assessment, early detection, prognosis, and management. Herein, we review data on BBBMs that are closest to clinical implementation, particularly those based on measures of amyloid-β peptides and phosphorylated tau species. We discuss key parameters and considerations for the development and potential deployment of these BBBMs under different contexts of use and highlight challenges at the methodological, clinical, and regulatory levels.
UR - http://www.scopus.com/inward/record.url?scp=85163280053&partnerID=8YFLogxK
U2 - 10.1016/j.neuron.2023.05.017
DO - 10.1016/j.neuron.2023.05.017
M3 - Review article
C2 - 37295421
AN - SCOPUS:85163280053
SN - 0896-6273
VL - 111
SP - 2781
EP - 2799
JO - Neuron
JF - Neuron
IS - 18
ER -